
Erasca Faces Securities Class Action Over Misleading Drug Development Claims
Investors who purchased Erasca, Inc. shares between January 14, 2025, and April 26, 2026, are being urged to join a class action lawsuit. The litigation alleges the company violated the Securities Exchange Act by issuing false statements regarding its experimental drug candidate, ERAS-0015.
























